This announcement is a separate document:
康泰生物：关于公司四价流感病毒裂解疫苗（MDCK细胞）临床试验申请获得受理的公告
Shenzhen Kangtai Biological Products: Announcement on the acceptance of clinical trial application for the quadrivalent influenza virus split vaccine (MDCK cell) of the company.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.